Literature DB >> 9396264

[A case of primary mediastinal choriocarcinoma].

Y Nakahara1, K Fukuyama, M Kojima, M Nagata, S Matsubara, M Tominaga, K Naitoh, S Hayashi.   

Abstract

A 27-year-old man with primary mediastinal choriocarcinoma was reported. He was admitted with complaint of right chest pain and dyspnea. Chest X-ray film and computed tomography of the chest revealed a bulky mass at anterior mediastinum and right pleural effusion. Physical examination revealed bilateral gynecomastia, and the serum beta-HCG level was cap at 500 ng/ml. The specimens obtained by percutaneous needle biopsy of the mediastinal mass showed cytotrophoblasts and syncytiotrophoblasts. He received 4 cycles of anti-cancer chemotherapy, and underwent resection for a residual mass, in which viable cancer cells remained in histological examination. In spite of additional chemotherapy, multiple lung metastasis developed rapidly. High dose chemotherapy, with carboplatine (200 mg/m2 x 4 days), etoposide (250 mg/m2 x 4 days) and cyclophosphamide (50 mg/kg x 2 days) was performed in combination with peripheral blood stem cell autotransplantation. However, brain metastasis set in and he died of respiratory failure 9 months after the onset of symptoms.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9396264

Source DB:  PubMed          Journal:  Nihon Kyobu Shikkan Gakkai Zasshi        ISSN: 0301-1542


  2 in total

1.  Primary choriocarcinoma in mediastinum with multiple lung metastases in a male patient: A case report and a review of the literature.

Authors:  Song Zhang; Hui Gao; Xin-An Wang; Bin Liang; Dao-Wei Li; Yang Shao; Shu-Juan Jiang
Journal:  Thorac Cancer       Date:  2014-08-25       Impact factor: 3.500

2.  Primary Mediastinal Germ Cell Tumors-The University of Western Ontario Experience.

Authors:  Arnon Lavi; Eric Winquist; Shiva M Nair; Joseph L Chin; Jonathan Izawa; Ricardo Fernandes; Scott Ernst; Nicholas E Power
Journal:  Curr Oncol       Date:  2020-12-08       Impact factor: 3.677

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.